Erasca Inc (ERAS)

$13.02 +0.48 (3.83%)
Market Cap 3.88B
Revenue (ttm) 0.00
Net Income (ttm) -161.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,559,200
Avg Vol 5,914,352
Day's Range N/A - N/A
Shares Out 309.59M
Stochastic %K 61%
Beta 1.21
Analysts Strong Sell
Price Target $11.55

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 465 6511
Address:
3115 Merryfield Row, Suite 300, San Diego, United States
sasanalyst
sasanalyst Feb. 23 at 10:34 PM
$ERAS This will be a juicy acquisition for Merck $MRK as now they split their Oncology business. Looks like they want to do multiple small acquisitions after opting out of the RAS pioneer $RVMD
1 · Reply
dixiebull
dixiebull Feb. 23 at 9:58 PM
$IBRX ran to m11 target, vwap is 10 so if it can break back over that, it can run again to 11 and maybe 12 $ERAS ran to 13, see if that holdsnow for 13.50 to 14 $CDIO has res at 3.20 once over 3, so see if 2.80 holds for a break of 3 to 3.25 and 3.50 $NAMM will watch to see if 3.50 holds for a move to 3.85 and 4.15 $VNDA made it to 9.09 not as strong as i thought, but see if 8 holds for a break of 8.50 back to 9
0 · Reply
OptionRunners
OptionRunners Feb. 18 at 5:31 PM
$ERAS more call buying
0 · Reply
1SwingSensei
1SwingSensei Feb. 18 at 5:23 AM
$ERAS I am enjoying this ride... What say you?
0 · Reply
DavyDaveCharts
DavyDaveCharts Feb. 17 at 10:49 PM
$ERAS well damn!
0 · Reply
zzzdoc01
zzzdoc01 Feb. 17 at 9:41 PM
$RVMD $ERAS not far behind today...
0 · Reply
topstockalerts
topstockalerts Feb. 12 at 7:47 PM
$ERAS Watching for the next breakout leg 👀. Price is holding tight near highs. That usually leads to expansion.
0 · Reply
KUMO2026
KUMO2026 Feb. 12 at 7:42 PM
$ERAS the market today can’t stop this train
0 · Reply
HIGHTABLETRADES
HIGHTABLETRADES Feb. 12 at 5:30 PM
$ERAS shorts are soon to be hot hot and fleeing.
0 · Reply
Quantumup
Quantumup Feb. 9 at 1:58 PM
Stifel reit'd $ERAS Buy-$10 & provided its takeaways after🗣️w/ CFO/CBO. $RVMD $BBOT $DAWN MRK NVS $IMRX We hosted a fireside chat with Erasca's CFO/CBO David Chacko during the 2026 Stifel Biotech Ski Summit in Park Clty (February 2-4). See main takeaways below: panRAS competitive landscape — why hasn't pharma brought forward a pan-RAS? ERAS views RVMD as a trailblazer with themselves solidly in second place; secured COM in 10/2025. ERAS-0015 is optimized for PK and potency; competitors who enhance one over the other could see diminishing returns (e.g. less favorable therapeutic index). The tri-complex chemistry and IP make it very difficult to bring forward a novel pan-RAS — a lot easier to make a new pan-KRAS. ERAS is very complimentary of the medicinal chemistry heavy lifting of WuXi who discovered ERAS-0015. Competition from China is less of a concern for pan-RAS molecular glues — 'never say never', but do not expect a surge of Chinese 'me too' assets we saw with the KRAS G12C class.
0 · Reply
Latest News on ERAS
Erasca to Present at Upcoming Conferences in February

Feb 5, 2026, 8:00 AM EST - 18 days ago

Erasca to Present at Upcoming Conferences in February

Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?

Jan 26, 2026, 7:52 AM EST - 4 weeks ago

Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 23, 2026, 4:01 PM EST - 4 weeks ago

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 8:54 PM EST - 4 weeks ago

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

Jan 20, 2026, 4:01 PM EST - 4 weeks ago

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Jan 12, 2026, 8:00 AM EST - 6 weeks ago

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

What's Going With Cancer Biotech Erasca Stock On Thursday?

Jan 8, 2026, 1:21 PM EST - 6 weeks ago

What's Going With Cancer Biotech Erasca Stock On Thursday?

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 9:08 AM EST - 3 months ago

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Nov 12, 2025, 4:01 PM EST - 3 months ago

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Nov 6, 2025, 8:00 AM EST - 3 months ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Erasca to Present at Upcoming Conferences in November

Nov 4, 2025, 8:00 AM EST - 3 months ago

Erasca to Present at Upcoming Conferences in November

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Jun 2, 2025, 8:00 AM EDT - 9 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Erasca to Present at Upcoming Investor Conferences in June

May 29, 2025, 8:00 AM EDT - 9 months ago

Erasca to Present at Upcoming Investor Conferences in June

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 4:05 PM EDT - 10 months ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 13, 2025, 8:00 AM EDT - 10 months ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

Erasca to Present at the Bank of America Securities Health Care Conference

May 7, 2025, 8:00 AM EDT - 10 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Apr 29, 2025, 4:05 PM EDT - 10 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 10 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 11 months ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 1 year ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27, 2025, 12:09 AM EST - 1 year ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 21, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 16, 2024, 8:00 PM EDT - 1 year ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 8, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca to Present at the Bank of America Health Care Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Health Care Conference

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 29, 2024, 11:11 AM EDT - 2 years ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 8:30 PM EDT - 2 years ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Dec 11, 2023, 8:00 AM EST - 2 years ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 28, 2023, 8:00 AM EST - 2 years ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 9, 2023, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Erasca to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at Upcoming Investor Conferences in November

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Aug 28, 2023, 6:05 AM EDT - 2 years ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

Aug 14, 2023, 3:22 PM EDT - 2 years ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

CVX PUMP

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 22, 2023, 4:01 PM EDT - 2 years ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 31, 2023, 8:00 AM EDT - 2 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

sasanalyst
sasanalyst Feb. 23 at 10:34 PM
$ERAS This will be a juicy acquisition for Merck $MRK as now they split their Oncology business. Looks like they want to do multiple small acquisitions after opting out of the RAS pioneer $RVMD
1 · Reply
dixiebull
dixiebull Feb. 23 at 9:58 PM
$IBRX ran to m11 target, vwap is 10 so if it can break back over that, it can run again to 11 and maybe 12 $ERAS ran to 13, see if that holdsnow for 13.50 to 14 $CDIO has res at 3.20 once over 3, so see if 2.80 holds for a break of 3 to 3.25 and 3.50 $NAMM will watch to see if 3.50 holds for a move to 3.85 and 4.15 $VNDA made it to 9.09 not as strong as i thought, but see if 8 holds for a break of 8.50 back to 9
0 · Reply
OptionRunners
OptionRunners Feb. 18 at 5:31 PM
$ERAS more call buying
0 · Reply
1SwingSensei
1SwingSensei Feb. 18 at 5:23 AM
$ERAS I am enjoying this ride... What say you?
0 · Reply
DavyDaveCharts
DavyDaveCharts Feb. 17 at 10:49 PM
$ERAS well damn!
0 · Reply
zzzdoc01
zzzdoc01 Feb. 17 at 9:41 PM
$RVMD $ERAS not far behind today...
0 · Reply
topstockalerts
topstockalerts Feb. 12 at 7:47 PM
$ERAS Watching for the next breakout leg 👀. Price is holding tight near highs. That usually leads to expansion.
0 · Reply
KUMO2026
KUMO2026 Feb. 12 at 7:42 PM
$ERAS the market today can’t stop this train
0 · Reply
HIGHTABLETRADES
HIGHTABLETRADES Feb. 12 at 5:30 PM
$ERAS shorts are soon to be hot hot and fleeing.
0 · Reply
Quantumup
Quantumup Feb. 9 at 1:58 PM
Stifel reit'd $ERAS Buy-$10 & provided its takeaways after🗣️w/ CFO/CBO. $RVMD $BBOT $DAWN MRK NVS $IMRX We hosted a fireside chat with Erasca's CFO/CBO David Chacko during the 2026 Stifel Biotech Ski Summit in Park Clty (February 2-4). See main takeaways below: panRAS competitive landscape — why hasn't pharma brought forward a pan-RAS? ERAS views RVMD as a trailblazer with themselves solidly in second place; secured COM in 10/2025. ERAS-0015 is optimized for PK and potency; competitors who enhance one over the other could see diminishing returns (e.g. less favorable therapeutic index). The tri-complex chemistry and IP make it very difficult to bring forward a novel pan-RAS — a lot easier to make a new pan-KRAS. ERAS is very complimentary of the medicinal chemistry heavy lifting of WuXi who discovered ERAS-0015. Competition from China is less of a concern for pan-RAS molecular glues — 'never say never', but do not expect a surge of Chinese 'me too' assets we saw with the KRAS G12C class.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 9 at 11:47 AM
$ERAS Current Stock Price: $12.29 Contracts to trade: $12.5 ERAS Feb 20 2026 Call Entry: $0.85 Exit: $1.42 ROI: 66% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
UgoGreg
UgoGreg Feb. 8 at 5:29 PM
$ERAS https://youtu.be/ygBN8MilTyc
1 · Reply
UgoGreg
UgoGreg Feb. 8 at 4:06 PM
$ERAS https://youtu.be/b4CDDEB3OQo
0 · Reply
My_Lai_1968
My_Lai_1968 Feb. 6 at 3:12 PM
$ERAS Does ERAS still have a monopoly on manufacturing counterfeit caramel nougat and raspberry swirl mini-pies, sold exclusively to mentally disabled violent criminals in high-security El Salvador penile institutions who crave sweets while soiling their pants? This is a very serious question and I will not tolerate responses that show disrespect in any way!
0 · Reply
OnTheBalance
OnTheBalance Feb. 6 at 6:02 AM
$ERAS no responses.. ? They were mouthing off not long ago
1 · Reply
sasanalyst
sasanalyst Feb. 6 at 12:29 AM
$ERAS Not bad at all
0 · Reply
Nassertio
Nassertio Feb. 5 at 10:13 PM
$ERAS
0 · Reply
OnTheBalance
OnTheBalance Feb. 5 at 10:02 PM
$ERAS Not bad at all
0 · Reply
OnTheBalance
OnTheBalance Feb. 5 at 10:00 PM
$ERAS Just checking up on the brave SHORTIES health.. recall some were pretty mouthy recently
0 · Reply
CDMO
CDMO Feb. 5 at 8:39 PM
$ERAS wow
0 · Reply
LIVE_Trading
LIVE_Trading Feb. 5 at 8:05 PM
$ERAS support $12.14
0 · Reply
LIVE_Trading
LIVE_Trading Feb. 5 at 8:00 PM
bought $ERAS $SPY $NVDA $TSLA $QQQ
0 · Reply